Spotlight On... Expert says diabetes and rheumatoid arthritis are top therapeutic areas for drug delivery innovation; and more...

Neil Camish of Research Triangle, NC, consultancy International Device Solutions said that therapeutic areas related to drugs that are difficult to deliver manually are the biggest drug delivery opportunities, citing diabetes and rheumatoid arthritis as examples. "They fall into two general categories: Long-acting release therapies (e.g., Bydureon), which involve complex user setups, and viscous drug products, which include long chain molecules, oily suspensions or microspheres. This latter category contains larger molecules with higher dosage concentrations, which cause discomfort or pain during injection," he said in a Q&A interview. More

> Camargo Pharmaceutical Services and Medicines360 have gained FDA approval for their levonorgestrel-releasing hormonal intrauterine contraceptive device. More

Suggested Articles

Alexion's 100 mg/ml Ultomiris formulation is expected to slash infusion times by about 60% and bodes well for a planned subcutaneous version, too.

Kindeva, which produces inhalers, transdermal patches and other medical devices, is expanding operations in the St. Paul, Minnesota, area.

Adept at delivering drugs to the lower small intestine and colon, Evonik launched a platform that can deploy drugs to the upper small intestine, too.